MRC Technology and Oxford University Collaborate to Develop Novel Pain Therapeutics for Migraine
MRC Technology, a technology transfer organisation, announced it is collaborating with Dr Zameel Cader at Oxford University’s Nuffield Department of Clinical Neurosciences, to screen selective and potent potassium channel activators to develop novel therapeutic interventions in migraine. Drawing on MRC Technology’s commercialisation expertise in drug discovery, the project focusses on bringing to clinic more effective pain treatments arising from the work of Dr Cader’s group in identifying KCNK18, the first gene underlying typical migraine.
KCNK18 encodes a tandem-pore background potassium channel, TRESK, which is linked to causing migraines and controls the sensitivity of pain nerves in the brain. If TRESK is faulty or inactive, the body’s threshold to pain can be significantly lowered. Migraine is the most common neurological disorder, with prevalence estimated at 18.2% in females and 6.5% in males, and is characterised by a severe, recurring headache, often accompanied by nausea, vomiting and increased sensitivity to light and sound.
Dr Justin Bryans at MRC Technology, said: “We are delighted to be working with Dr Cader and his team who have made such a significant discovery in the underlying causes of migraine. We are hopeful that our collaboration will lead to treatments that could not only prevent migraines, but could potentially result in a more general pain therapy with even wider impact."
“Migraine is a major cause of disability worldwide and it has been estimated to be the most costly neurological disorder in Europe,” commented Dr Cader. “We have made a major step forward in our understanding of why people suffer with migraine and with MRC Technology’s wealth of drug discovery experience, we look forward to working with them to bring novel treatments to market.”
Most read news
Organizations

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.